Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), the leading horizontal platform for cell programming, today announced its results for the first quarter ended March 31, 2022. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.
"We sometimes remark that the pace of change never seems to slow at Ginkgo, and the beginning of 2022 has been no exception," said Jason Kelly, co-founder and CEO of Ginkgo. "We added 11 new programs in our cell programming business in the first quarter of 2022, including in many novel areas of work, and realized record revenues in our biosecurity business. We believe we are well positioned for this market downturn and expect to continue to invest in platform growth, both organically and through M&A, while ensuring we maintain a healthy balance sheet. We are particularly excited about our planned transactions with Bayer, in which they will be establishing a flagship partnership with Ginkgo in the field of agricultural biologicals and transferring their physical platform and team to Ginkgo to extend our platform capabilities in this field. We expect to see strategic moves like this in other industries in the coming years."
Recent Business Highlights & Strategic Positioning
First Quarter 2022 Financial Highlights
Full Year 2022 Guidance
Conference Call Details
Ginkgo will host a videoconference today, Monday, May 16, 2022, beginning at 4:30 p.m. ET. The presentation will include an overview of the first quarter financial performance, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session.
To ask a question ahead of the presentation, please submit your questions to @Ginkgo on Twitter (hashtag #GinkgoResults) or by sending an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it..
A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.
Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/
Audio-Only Dial Ins:
+1 646 876 9923 (New York)
+1 301 715 8592 (Washington DC)
+1 312 626 6799 (Chicago)
+1 669 900 6833 (San Jose)
+1 253 215 8782 (Tacoma)
+1 346 248 7799 (Houston)
+1 408 638 0968 (San Jose)
Webinar ID: 928 8373 1262
If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our web site at https://investors.ginkgobioworks.com/events/ for updated dial-in information.
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization, and therapeutics discovery. For more information, visitwww.ginkgobioworks.com.
Forward-Looking Statements of Ginkgo Bioworks
This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, current expectations, operations and anticipated results of operations, both business and financial, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the effect of Ginkgo's business combination with Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's business relationships, performance, and business generally, (ii) risks that the business combination disrupts current plans of Ginkgo and potential difficulties in Ginkgo's employee retention, (iii) the outcome of any legal proceedings that may be instituted against Ginkgo related to its business combination with Soaring Eagle, (iv) volatility in the price of Ginkgo's securities now that it is a public company due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo's business, changes in the combined capital structure and expectations associated with increases in the number of shares available for sale, (v) the ability to implement business plans, forecasts, and other expectations after the completion of the business combination, and ability to identify and realize additional opportunities, (vi) the risk of downturns in demand for products using synthetic biology, (vii) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, and (viii) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on March 29, 2022, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
Use of Non-GAAP Financial Measures
Certain of the financial measures included in this release, including Adjusted EBITDA, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.
MEDIA CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Ginkgo Bioworks Holdings, Inc. | ||||
Condensed Consolidated Balance Sheets | ||||
(in thousands, except per share data, unaudited) | ||||
As of March 31, | As of December 31, | |||
2022 | 2021 | |||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ 1,492,971 | $ 1,550,004 | ||
Accounts receivable, net | 167,256 | 131,544 | ||
Accounts receivable - related parties | 3,814 | 4,598 | ||
Inventory, net | 8,697 | 3,362 | ||
Prepaid expenses and other current assets | 33,094 | 33,537 | ||
Total current assets | 1,705,832 | 1,723,045 | ||
Property and equipment, net | 149,171 | 145,770 | ||
Investments | 103,031 | 102,037 | ||
Equity method investments | 8,207 | 13,194 | ||
Intangible assets, net | 20,829 | 21,642 | ||
Goodwill | 21,040 | 21,312 | ||
Other non-current assets | 49,616 | 43,990 | ||
Total assets | $ 2,057,726 | $ 2,070,990 | ||
Liabilities and Stockholders' Equity | ||||
Current liabilities: | ||||
Accounts payable | $35,257 | $8,189 | ||
Deferred revenue | 35,232 | 33,240 | ||
Accrued expenses and other current liabilities | 88,758 | 93,332 | ||
Total current liabilities | 159,247 | 134,761 | ||
Non-current liabilities: | ||||
Deferred rent, net of current portion | 19,262 | 18,746 | ||
Deferred revenue, net of current portion | 170,176 | 155,991 | ||
Lease financing obligation | 27,309 | 22,283 | ||
Warrant liabilities | 50,803 | 135,838 | ||
Other non-current liabilities | 16,881 | 35,992 | ||
Total liabilities | 443,678 | 503,611 | ||
Commitments and contingencies | ||||
Stockholders' equity: | ||||
Preferred stock, $0.0001 par value | — | — | ||
Common stock, $0.0001 par value | 162 | 161 | ||
Additional paid-in capital | 4,471,418 | 3,804,844 | ||
Accumulated deficit | (2,888,430) | (2,297,925) | ||
Accumulated other comprehensive loss | (2,355) | (1,715) | ||
Total Ginkgo Bioworks Holdings, Inc. stockholders' equity | 1,580,795 | 1,505,365 | ||
Non-controlling interest | 33,253 | 62,014 | ||
Total stockholders' equity | 1,614,048 | 1,567,379 | ||
Total liabilities and stockholders' equity | $ 2,057,726 | $ 2,070,990 | ||
Ginkgo Bioworks Holdings, Inc. | ||||
Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||
(in thousands, except share and per share data, unaudited) | ||||
Three Months Ended March 31, | ||||
2022 | 2021 | |||
Foundry revenue | $ 21,488 | $ 22,504 | ||
Biosecurity revenue: | ||||
Product | 13,947 | 5,775 | ||
Service | 132,970 | 15,818 | ||
Total revenue | 168,405 | 44,097 | ||
Costs and operating expenses: | ||||
Cost of Biosecurity product revenue | 8,095 | 9,935 | ||
Cost of Biosecurity service revenue | 77,337 | 13,765 | ||
Research and development | 322,720 | 59,585 | ||
General and administrative | 434,768 | 17,927 | ||
Total operating expenses | 842,920 | 101,212 | ||
Loss from operations | (674,515) | (57,115) | ||
Other income (expense): | ||||
Interest expense, net | (397) | (475) | ||
Loss on equity method investments | (20,887) | (28,624) | ||
Gain on investments | 450 | 12,622 | ||
Change in fair value of warrant liabilities | 85,035 | — | ||
Gain on deconsolidation of subsidiary | 15,900 | — | ||
Other income (expense), net | 1,637 | (1,345) | ||
Total other income (expense), net | 81,738 | (17,822) | ||
Loss before income taxes | (592,777) | (74,937) | ||
Income tax benefit | (184) | (159) | ||
Net loss | (592,593) | (74,778) | ||
Net loss attributable to non-controlling interest | (2,088) | (1,209) | ||
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders | $ (590,505) | $ (73,569) | ||
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders, basic and diluted | $ (0.37) | $ (0.06) | ||
Weighted average common shares outstanding, basic and diluted | 1,607,499,887 | 1,290,282,994 | ||
Comprehensive loss: | ||||
Net loss | $ (592,593) | $ (74,778) | ||
Other comprehensive loss: | ||||
Foreign currency translation adjustment | (640) | — | ||
Total other comprehensive loss | (640) | — | ||
Comprehensive loss | $ (593,233) | $ (74,778) | ||
Ginkgo Bioworks Holdings, Inc. | ||||
Condensed Consolidated Statements of Cash Flows | ||||
(in thousands, unaudited) | ||||
Three Months Ended March 31, | ||||
2022 | 2021 | |||
Cash flows from operating activities: | ||||
Net loss | $ (592,593) | $ (74,778) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Depreciation and amortization | 9,488 | 5,629 | ||
Stock-based compensation | 652,821 | 118 | ||
Loss on equity method investments | 20,887 | 28,624 | ||
Gain on investments | (450) | (12,622) | ||
Change in fair value of loans receivable | (584) | 1,825 | ||
Change in fair value of warrant liabilities | (85,035) | — | ||
Change in fair value of contingent consideration liability | 1,513 | — | ||
Gain on deconsolidation of subsidiary | (15,900) | — | ||
Other non-cash activity | 104 | — | ||
Changes in operating assets and liabilities: | ||||
Accounts receivable | (34,928) | (9,541) | ||
Prepaid expenses and other current assets | 700 | 1,633 | ||
Inventory | (5,335) | (681) | ||
Other non-current assets | 2,212 | (678) | ||
Accounts payable | 26,250 | 516 | ||
Accrued expenses and other current liabilities | 9,973 | 16,807 | ||
Deferred revenue, current and non-current | 11,444 | (5,512) | ||
Deferred rent, non-current | 516 | 688 | ||
Other non-current liabilities | (20,981) | (159) | ||
Net cash used in operating activities | (19,898) | (48,131) | ||
Cash flows from investing activities: | ||||
Purchases of property and equipment | (3,580) | (21,935) | ||
Prepayment for marketable equity securities | (3,691) | — | ||
Deconsolidation of subsidiary - cash | (28,772) | — | ||
Prepayment for business acquisition | — | (1,210) | ||
Other | 58 | 99 | ||
Net cash used in investing activities | (35,985) | (23,046) | ||
Cash flows from financing activities: | ||||
Proceeds from exercise of stock options | 75 | 27 | ||
Taxes paid related to net share settlement of equity awards | (981) | — | ||
Principal payments on capital leases and lease financing obligation | (286) | (285) | ||
Payment of deferred offering costs | — | (175) | ||
Net cash used in financing activities | (1,192) | (433) | ||
Effect of foreign exchange rates on cash and cash equivalents | (8) | — | ||
Net decrease in cash, cash equivalents and restricted cash | (57,083) | (71,610) | ||
Cash and cash equivalents, beginning of period | 1,550,004 | 380,801 | ||
Restricted cash, beginning of period | 42,924 | 5,076 | ||
Cash, cash equivalents and restricted cash, beginning of period | 1,592,928 | 385,877 | ||
Cash and cash equivalents, end of period | 1,492,971 | 308,128 | ||
Restricted cash, end of period | 42,874 | 6,139 | ||
Cash, cash equivalents and restricted cash, end of period | $ 1,535,845 | $ 314,267 | ||
Ginkgo Bioworks Holdings, Inc. | |||||
Selected Non-GAAP Financial Measures | |||||
(in thousands, unaudited) | |||||
Three Months Ended March 31, | |||||
2022 | 2021 | ||||
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders | $ (590,505) | $ (73,569) | |||
Interest expense, net | 397 | 475 | |||
Income tax benefit | (184) | (159) | |||
Depreciation and amortization | 9,488 | 5,629 | |||
EBITDA | (580,804) | (67,624) | |||
Stock-based compensation (1) | 659,035 | 118 | |||
Loss on equity method investments (2) | 20,264 | 27,415 | |||
Gain on investments (3) | (450) | (12,622) | |||
Change in fair value of warrant liabilities | (85,035) | — | |||
Gain on deconsolidation of subsidiary | (15,900) | — | |||
Other (4) | 939 | 1,575 | |||
Adjusted EBITDA | $ (1,951) | $ (51,138) | |||
(1) | For the three months ended March 31, 2022, includes $6.2 million in employer payroll taxes. |
(2) | For the three months ended March 31, 2022 and 2021, represents losses on equity method investments under the hypothetical liquidation at book value method of $20.9 million and $28.6 million, respectively, net of losses attributable to non-controlling interests. |
(3) | Includes gain on the change in fair value of our common stock investments in Synlogic and Cronos and warrants to purchase Synlogic common stock, which are all carried at fair value. |
(4) | For the three months ended March 31, 2022, includes a $0.6 million gain on the change in fair value of the Access Bio Convertible Notes offset by $1.5 million loss on the change in fair value of contingent consideration liability related to a business acquisition. For the three months ended March 31, 2021, includes $2.1 million loss on the change in fair value of the Access Bio Convertible Notes offset by a $0.5 million gain related to a settlement payment from Amyris. |
Ginkgo Bioworks Holdings, Inc. | |||
Segment Information | |||
(in thousands, unaudited) | |||
Three Months Ended March 31, | |||
2022 | 2021 | ||
Revenue: | |||
Foundry | $ 21,488 | $ 22,504 | |
Biosecurity | 146,917 | 21,593 | |
Total revenue | 168,405 | 44,097 | |
Segment cost of revenue: | |||
Biosecurity | 85,432 | 23,700 | |
Segment research and development expense: | |||
Foundry | 47,289 | 30,894 | |
Biosecurity | 517 | 23,403 | |
Total segment research and development expense | 47,806 | 54,297 | |
Segment general and administrative expense: | |||
Foundry | 26,693 | 13,155 | |
Biosecurity | 13,235 | 4,535 | |
Total segment general and administrative expense | 39,928 | 17,690 | |
Segment operating income (loss): | |||
Foundry | (52,494) | (21,545) | |
Biosecurity | 47,733 | (30,045) | |
Total segment operating income (loss) | (4,761) | (51,590) | |
Operating expenses not allocated to segments: | |||
Stock-based compensation (1) | 659,035 | 118 | |
Depreciation and amortization | 9,206 | 5,407 | |
Change in fair value of contingent consideration liability | 1,513 | — | |
Loss from operations | $ (674,515) | $ (57,115) | |
(1) For the three months ended March 31, 2022, includes $6.2 million in employer payroll taxes. | |||
| Last Trade: | US$10.08 |
| Daily Change: | 1.34 15.33 |
| Daily Volume: | 2,616,130 |
| Market Cap: | US$455.620M |
November 12, 2024 November 12, 2024 September 24, 2024 September 18, 2024 September 17, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
